Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Current Assets (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Current Assets for 13 consecutive years, with $354.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets rose 204.51% to $354.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $354.7 million, a 204.51% increase, with the full-year FY2024 number at $161.1 million, changed N/A from a year prior.
  • Current Assets was $354.7 million for Q3 2025 at Theravance Biopharma, down from $366.3 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $511.7 million in Q3 2022 to a low of $116.5 million in Q3 2024.
  • A 5-year average of $244.4 million and a median of $204.6 million in 2022 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: tumbled 68.4% in 2023, then skyrocketed 207.02% in 2025.
  • Theravance Biopharma's Current Assets stood at $297.2 million in 2021, then increased by 18.94% to $353.5 million in 2022, then tumbled by 54.26% to $161.7 million in 2023, then fell by 0.39% to $161.1 million in 2024, then soared by 120.22% to $354.7 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Current Assets are $354.7 million (Q3 2025), $366.3 million (Q2 2025), and $150.3 million (Q1 2025).